FDA Expands Approval of Cardiac Ultrasound Imaging Agent for Pediatric Patients

News
Article

The only ultrasound enhancing agent that does not contain polyethylene glycol, Optison may now be utilized to enhance echocardiogram assessment of ventricular function in pediatric patients.

The Food and Drug Administration (FDA) has approved an expanded indication that allows use of ultrasound enhancing agent Optison for pediatric patients with suboptimal echocardiograms.

Through the use of gas-filled microbubbles, Optison improves the visualization of heart chambers and endocardial borders, according to GE HealthCare, the manufacturer of Optison.

FDA Expands Approval of Cardiac Ultrasound Imaging Agent for Pediatric Patients

Recently approved for use in pediatric patients, the ultrasound enhancing agent Optison provided enhanced visualization of endocardial borders and ventricular wall segments for pediatric patients in a recent phase IV study. (Image courtesy of GE HealthCare.)

Originally approved by the FDA in 1997 for adult patients, Optison was the subject of a recent phase IV multicenter study. GE HealthCare said the study results revealed the effectiveness of the ultrasound enhancing agent in improving delineation of endocardial borders as well as imaging of ventricular wall segments in pediatric patients.

“Ultrasound enhancing agents have significantly advanced diagnostic quality in adult echocardiography over the years, and we are now seeing promising research supporting their safe and effective use in pediatric patients,” said Arash Sabati, MD, FACC, a pediatric cardiologist and non-invasive imaging specialist at Phoenix Children’s. “The availability of agents like Optison will further enhance diagnostic imaging for pediatric patients, helping to ensure the best possible care.”

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Nina Kottler, MD, MS
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2025 MJH Life Sciences

All rights reserved.